TherapeuticsMD Inc. [NASDAQ: TXMD] gained 4.24% on the last trading session, reaching $1.23 price per share at the time. The company report on May 25, 2021 that TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA.
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, announced that the Company submitted a supplemental New Drug Application (“sNDA”) for BIJUVA (estradiol and progesterone) capsules, 0.5 mg/100 mg, to the U.S. Food and Drug Administration (“FDA”).
The Company expects to learn of the acceptance of the sNDA upon receipt of the Filing Review Notification from the FDA, approximately 74 days after submission. If accepted, the Company expects that the review time under the Prescription Drug User Fee Act (PDUFA) will be within ten months of receipt by the FDA, approximately March 21, 2022.
TherapeuticsMD Inc. represents 393.19 million in outstanding shares, while the company has a total market value of $483.60 million with the latest information. TXMD stock price has been found in the range of $1.16 to $1.23.
If compared to the average trading volume of 10.72M shares, TXMD reached a trading volume of 5483025 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about TherapeuticsMD Inc. [TXMD]:
Jefferies have made an estimate for TherapeuticsMD Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on August 07, 2020. The new note on the price target was released on May 19, 2020, representing the official price target for TherapeuticsMD Inc. stock.
The Average True Range (ATR) for TherapeuticsMD Inc. is set at 0.07, with the Price to Sales ratio for TXMD stock in the period of the last 12 months amounting to 6.67.
Trading performance analysis for TXMD stock
TherapeuticsMD Inc. [TXMD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.96. With this latest performance, TXMD shares gained by 6.03% in over the last four-week period, additionally sinking by -4.65% over the last 6 months – not to mention a rise of 3.36% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TXMD stock in for the last two-week period is set at 54.51, with the RSI for the last a single of trading hit 60.01, and the three-weeks RSI is set at 50.96 for TherapeuticsMD Inc. [TXMD]. The present Moving Average for the last 50 days of trading for this stock 1.2459, while it was recorded at 1.2180 for the last single week of trading, and 1.4133 for the last 200 days.
TherapeuticsMD Inc. [TXMD]: A deeper dive into fundamental analysis
TherapeuticsMD Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.90 and a Current Ratio set at 3.10.
TherapeuticsMD Inc. [TXMD]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, TherapeuticsMD Inc. posted -0.19/share EPS, while the average EPS was predicted by analysts to be reported at -0.17/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -11.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TXMD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for TherapeuticsMD Inc. go to 17.60%.
An analysis of insider ownership at TherapeuticsMD Inc. [TXMD]
There are presently around $214 million, or 45.80% of TXMD stock, in the hands of institutional investors. The top three institutional holders of TXMD stocks are: BLACKROCK INC. with ownership of 27,597,421, which is approximately 28.844% of the company’s market cap and around 5.10% of the total institutional ownership; PRICE T ROWE ASSOCIATES INC /MD/, holding 18,312,987 shares of the stock with an approximate value of $22.52 million in TXMD stocks shares; and VANGUARD GROUP INC, currently with $22.25 million in TXMD stock with ownership of nearly 37.413% of the company’s market capitalization.
90 institutional holders increased their position in TherapeuticsMD Inc. [NASDAQ:TXMD] by around 33,493,872 shares. Additionally, 53 investors decreased positions by around 20,409,954 shares, while 43 investors held positions by with 120,261,562 shares. The mentioned changes placed institutional holdings at 174,165,388 shares, according to the latest SEC report filing. TXMD stock had 28 new institutional investments in for a total of 5,613,200 shares, while 24 institutional investors sold positions of 12,805,245 shares during the same period.